Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Antibe's Stomach-Friendly NSAID Keeps Chugging Along

<< Previous

Bullboard Posts

Next >>

Post by Free55domon Apr 02, 2021 1:05pm

450 Views

Post# 32932252

Antibe's Stomach-Friendly NSAID Keeps Chugging Along

Phase 3 trials in Canada before even the most preliminary toxicology studies are run in humans. But in this case, where a novel class of an analgesic/anti-inflammatory drug is sorely needed, whatever gets them there fastest is just fine.

https://www.acsh.org/news/2021/03/31/antibes-stomach-friendly-nsaid-keeps-chugging-along-15442

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing